Ezzati Nazhad Dolatabadi Jafar, Hamishehkar Hamed, Eskandani Morteza, Valizadeh Hadi
Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran; Student research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmaceutical Technology Laboratory, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Colloids Surf B Biointerfaces. 2014 May 1;117:21-8. doi: 10.1016/j.colsurfb.2014.01.055. Epub 2014 Feb 9.
Solid lipid nanoparticles (SLNs) are novel drug delivery system for drug targeting in various routs of administration such as parenteral, oral, ophthalmic and topical. These carriers have some advantages such as high drug payload, increased drug stability, the possibility of incorporation of lipophilic and hydrophilic drugs, and low biotoxicity. In this study, alendronate sodium was used as a hydrophilic model drug and was incorporated into SLNs.
Hot homogenization method was used for preparation of alendronate sodium-loaded SLN formulations and the encapsulation efficiency of drug in SLNs was determined by ultrafiltration method using centrifugal devices. Scanning electron microscopy (SEM) was carried out to study the morphological behaviors of prepared SLNs like sphericity. Several cytotoxicity studies including MTT, DAPI staining and DNA fragmentation assays were used for biocompatibility assays.
High drug encapsulation efficiency (70-85%) was achieved by drug determination through derivatization with o-phthalaldehyde. The physical stability of drug-loaded SLNs in aqueous dispersions was assessed in terms of size and drug leakage during two weeks. Scanning electron microscopy images showed spherical particles in the nanometer range confirming the obtained data from size analyzer. Several cytotoxicity studies including MTT, DAPI staining and DNA fragmentation assays as well as flow cytometry analysis confirmed the low toxicity of alendronate-loaded SLNs.
The cost-efficient procedure, the avoidance of organic solvents application, acceptable reproducibility, ease of manufacturing under mild preparation conditions, high level of drug encapsulation, desirable physical stability and biocompatibility are the advantages of the proposed SLN formulations.
固体脂质纳米粒(SLNs)是一种新型药物递送系统,可用于多种给药途径的药物靶向,如肠胃外、口服、眼部和局部给药。这些载体具有一些优点,如高药物载量、提高药物稳定性、可包载亲脂性和亲水性药物以及低生物毒性。在本研究中,阿仑膦酸钠被用作亲水性模型药物并被载入固体脂质纳米粒。
采用热均质法制备载阿仑膦酸钠的固体脂质纳米粒制剂,并使用离心装置通过超滤法测定药物在固体脂质纳米粒中的包封率。进行扫描电子显微镜(SEM)以研究制备的固体脂质纳米粒的形态行为,如球形度。使用包括MTT、DAPI染色和DNA片段化分析在内的几种细胞毒性研究进行生物相容性分析。
通过邻苯二甲醛衍生化测定药物,实现了高药物包封率(70 - 85%)。从粒径和两周内药物泄漏方面评估了载药固体脂质纳米粒在水性分散体中的物理稳定性。扫描电子显微镜图像显示纳米级的球形颗粒,证实了从粒径分析仪获得的数据。包括MTT、DAPI染色和DNA片段化分析以及流式细胞术分析在内的几种细胞毒性研究证实了载阿仑膦酸钠固体脂质纳米粒的低毒性。
所提出的固体脂质纳米粒制剂的优点包括成本效益高的制备方法、避免使用有机溶剂、可接受的重现性、在温和制备条件下易于制造、高水平的药物包封、理想的物理稳定性和生物相容性。